Albert W. Gianchetti
Directeur Général chez Xylocor Therapeutics, Inc.
Profil
Albert W.
Gianchetti is currently the President, Chief Executive Officer & Director at Xylocor Therapeutics, Inc. He previously worked as the Chief Commercial Officer & Senior Vice President at Vanda Pharmaceuticals, Inc. from 2007 to 2008 and as the Vice President-Global Commercial Strategy at GSK Plc.
He holds an MBA degree from Drexel University and an undergraduate degree from the University of Delaware.
Postes actifs de Albert W. Gianchetti
| Sociétés | Poste | Début |
|---|---|---|
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Directeur Général | - |
Anciens postes connus de Albert W. Gianchetti
| Sociétés | Poste | Fin |
|---|---|---|
| VANDA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/12/2008 |
| GSK PLC | Corporate Officer/Principal | - |
Formation de Albert W. Gianchetti
| University of Delaware | Undergraduate Degree |
| Drexel University | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VANDA PHARMACEUTICALS INC. | Health Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
